Kolon TissueGene, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 48
- Market Cap
- -
- Website
- http://www.tissuegene.com
Clinical Trials
6
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (33.3%)Phase 2
2 (33.3%)Phase 3
2 (33.3%)Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease
Phase 1
Not yet recruiting
- Conditions
- Degenerative Disc Disease
- Interventions
- Biological: TG-C Low DoseBiological: TG-C High DoseBiological: TG-C Mid DoseBiological: Sham Control
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06144970
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis
Phase 2
Not yet recruiting
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Biological: Placebo Control
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT05276011
Study to Determine the Efficacy and Safety of TG-C in Subjects with Kellgren/Lawrence Grade 2 or 3 OA of the Knee
Phase 3
Active, not recruiting
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Biological: Placebo Control
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 531
- Registration Number
- NCT03291470
- Locations
- 🇺🇸
Nebojsa Skrepnik, Tucson, Arizona, United States
🇺🇸Steve Sitar, Anaheim, California, United States
🇺🇸Stuart Silverman, Beverly Hills, California, United States
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 OA of the Knee
Phase 3
Active, not recruiting
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Biological: Placebo Control
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 535
- Registration Number
- NCT03203330
- Locations
- 🇺🇸
Jeffrey Davis, Birmingham, Alabama, United States
🇺🇸Bradly Goodman, Birmingham, Alabama, United States
🇺🇸Saima Chohan, Phoenix, Arizona, United States
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
Phase 2
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Biological: TissueGene-CDrug: Normal Saline
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Kolon TissueGene, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01221441
- Locations
- 🇺🇸
Advent Clinical Research, Pinellas Park, Florida, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Rothman Institute, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- Next
News
No news found